Dyne Therapeutics price target raised to $37 from $33 at Guggenheim

Guggenheim raised the firm’s price target on Dyne Therapeutics (DYN) to $37 from $33 and keeps a Buy rating on the shares. Following January clinical data from the FORCE platform, the Street has been dissecting the ACHIEVE DM1 and DELIVER DMD data and the recent update from Avidity Biosciences (RNA) “implies an ACHEIVEable path to market,” says the analyst. Based on available data, DYNE-101 at 1.8 mg/kg appears equivalent to del-desiran at 4 mg/kg on the video hand opening time, or vHOT, endpoint, the analyst tells investors.